Evidence map›Paper›PMID 35643491›Full record

ArticleBMC women's health2022

Patient perspectives on delays in cervical cancer screening and follow-up care in Botswana: a mixed methods study.

Katharine A Rendle, Doreen Ramogola-Masire, Barati Monare, Shannon N Ogden, Hannah K Toneff, Chelsea A Saia, Jocelyn V Wainwright, Tara M Friebel-Klingner, Lisa Bazzett-Matabele, Rohini Bhatia and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC women's health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 2 countries.

Katharine A RendleDepartment of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA, USA.
Doreen Ramogola-MasireDepartment of Obstetrics and Gynecology and Office of Research and Graduate Studies, University of Botswana, Gaborone, Botswana.
Barati MonareBotswana-University of Pennsylvania Partnership, Gaborone, Botswana.
Shannon N OgdenDepartment of Health Law, Policy, and Management, Boston University, Boston, MA, USA.
Hannah K ToneffDepartment of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA, USA.
Chelsea A SaiaDepartment of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA, USA.
Jocelyn V WainwrightDepartment of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA, USA.
Tara M Friebel-KlingnerDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Lisa Bazzett-MatabeleDepartment of Obstetrics and Gynecology, University of Botswana, Gaborone, Botswana.
Rohini BhatiaDepartment of Radiation Oncology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Natalie BonnerUT Southwestern Medical School, Dallas, TX, USA.
Tlotlo B RalefalaDepartment of Oncology, Princess Marina Hospital, Gaborone, Botswana.
Peter VuylstekeDepartment of Internal Medicine, University of Botswana, Gaborone, Botswana.
Rebecca LuckettBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Surbhi GroverDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA. Surbhi.grover@pennmedicine.upenn.edu.
University of Botswana · BWUniversity of Pennsylvania Health System · USBeth Israel Deaconess Medical Center · USBoston University · USJohns Hopkins Medicine · USJohns Hopkins University · USThe University of Texas Southwestern Medical Center · USUniversity of Pennsylvania · US

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
Integrated Care for Addiction, HIV and HCV Research and Education (ICAHRE)T32DA041898 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Rachel Sayko Adams, Michael D Stein · 2017 to 2026
$3.8M
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrenceK08CA230170 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GROVER, SURBHI · 2019 to 2023
$1.4M
NCI NIH HHS K08 CA230170NIAID NIH HHS P30 AI045008NIDA NIH HHS T32 DA041898
6 · The paper itself

Abstract

backgroundDelays in screening and timely diagnosis contribute significantly to global disparities in cervical cancer mortality in Botswana and other low- and middle-income countries, particularly those with high rates of HIV. Little is known about the modifiable factors shaping these delays from the perspectives of women themselves and how these perspectives may differ between those living with and without HIV.

methodsFrom March-May 2019, we conducted a concurrent, mixed methods study of women receiving treatment for cervical cancer at a multidisciplinary oncology clinic in Botswana. Enrolled participants completed a one-time, concurrent semi-structured interview and structured questionnaire assessing patient characteristics, screening and HIV-related beliefs and knowledge, and barriers and facilitators to screening and follow-up care. Qualitative data were analyzed using directed content analysis guided by the Model of Pathways to Treatment and triangulated with quantitative questionnaire data to identify areas of convergence and divergence. Fisher's exact tests were used to explore associations between questionnaire data (e.g., screening knowledge) and HIV status.

resultsForty-two women enrolled in the study, 64% of whom were living with HIV and 26% were diagnosed with stage III cervical cancer. Median age was 45 years (IQR 54-67) in those living with HIV and 64 years (IQR 42-53) in those living without. Overall screening rates before symptomatic disease were low (24%). Median time from most proximal screen to diagnosis was 52 median days (IQR 15-176), with no significant differences by HIV status. General screening knowledge was higher among those living with HIV versus those without (100% vs 73%; p < 0.05), but knowledge about HPV and other risk factors was low in both groups. Similar to questionnaire results, qualitative results indicate limited awareness of the need to be screened prior to symptoms as a central barrier to timely screening. Some participants also noted that delays in the receipt of screening results and fear also contributed to treatment delays. However, many participants also described myriad sources of social and tangible support that helped them to overcome some of these challenges.

conclusionInterventions focused on increasing routine screening and supporting timely awareness and access to care are needed to reduce global disparities in cervical cancer.

Indexed as

HIV InfectionsUterine Cervical NeoplasmsAftercareBotswanaEarly Detection of CancerFemaleHumansMiddle AgedCervical cancerEarly detectionGlobal healthHIVMixed methods study

Identifiers

PMID35643491
PMCPMC9148477
OpenAlexW4281827986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.